Elliot Chartash
Impact in
- Rheumatology top 0.2%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Hematology top 1%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Rheumatology 15
- Rheumatoid Arthritis Research and Therapies 9
- Systemic Lupus Erythematosus Research 5
- Immunology 11
- T-cell and B-cell Immunology 7
- Immunotherapy and Immune Responses 4
- Immune Cell Function and Interaction 3
- Co-authors
- Steven A. Fischkoff (4 shared papers)Edward Clark Keystone (3 shared papers)Daniel E. Furst (3 shared papers)Charles A. Birbara (2 shared papers)Larry W. Moreland (2 shared papers)Michael H. Weisman (2 shared papers)Michael E. Weinblatt (2 shared papers)Leah S. Teoh (2 shared papers)
- Journals
- Annals of Oncology (7 papers)Seminars in Arthritis and Rheumatism (3 papers)Journal of Clinical Investigation (2 papers)The Journal of Immunology (2 papers)The Journal of Rheumatology (1 paper)
- Partner nations
- United StatesCanadaAustralia
In The Last Decade
Elliot Chartash
42 papers receiving 5.9k citations
Elliot Chartash's Hit Papers
Peers
Comparison fields: 5 of 121
- Rheumatology 2.9k
- Hematology 842
- Immunology 1.4k
- Oncology 1.6k
- Genetics 326
Countries citing papers authored by Elliot Chartash
This map shows the geographic impact of Elliot Chartash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliot Chartash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliot Chartash more than expected).
Fields of papers citing papers by Elliot Chartash
This network shows the impact of papers produced by Elliot Chartash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliot Chartash. The network helps show where Elliot Chartash may publish in the future.
Co-authors
The 25 scholars most cited alongside Elliot Chartash, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Hit paper breakdown → | 2003 | 1522 |
| 2 | PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma Hit paper breakdown → | 2016 | 1030 |
| 3 | Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial Hit paper breakdown → | 2004 | 1020 |
| 4 | Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. | 2005 | 434 |
| 5 | Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). | 2003 | 430 |
| 6 | 2003 | 257 | |
| 7 | 2021 | 230 | |
| 8 | 2020 | 132 | |
| 9 | 1989 | 125 | |
| 10 | 1992 | 89 | |
| 11 | 1996 | 85 | |
| 12 | 2014 | 71 | |
| 13 | 2016 | 66 | |
| 14 | 1994 | 63 | |
| 15 | 1999 | 61 | |
| 16 | Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. | 2008 | 59 |
| 17 | 2020 | 53 | |
| 18 | 2020 | 48 | |
| 19 | 1988 | 46 | |
| 20 | 1999 | 42 |
About Elliot Chartash
Elliot Chartash is a scholar working on Rheumatology, Immunology, Oncology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 42 papers that have together received 6.2k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (9 papers), Cancer Immunotherapy and Biomarkers (7 papers), T-cell and B-cell Immunology (7 papers), CAR-T cell therapy research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Systemic Lupus Erythematosus Research (5 papers), Immunotherapy and Immune Responses (4 papers) and Immune Cell Function and Interaction (3 papers). The work is most often cited by research in Rheumatology (2.9k citations), Hematology (842 citations), Immunology (1.4k citations), Oncology (1.6k citations) and Genetics (326 citations). Elliot Chartash has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Steven A. Fischkoff, Edward Clark Keystone, Daniel E. Furst, Charles A. Birbara, Larry W. Moreland, Michael H. Weisman, Michael E. Weinblatt, Leah S. Teoh, Hua Ye and H Tannenbaum. Their work appears in journals such as Annals of Oncology, Seminars in Arthritis and Rheumatism, Journal of Clinical Investigation, The Journal of Immunology and The Journal of Rheumatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.